Eli Lilly and Company (BIT:1LLY)

Market Cap	594.09B
Revenue (ttm)	45.34B
Net Income (ttm)	10.28B
Shares Out	n/a
EPS (ttm)	11.37
PE Ratio	57.82
Forward PE	30.99
Dividend	5.20 (0.78%)
Ex-Dividend Date	May 15, 2025

Volume	197
Average Volume	290
Open	681.40
Previous Close	679.40
Day's Range	669.00 - 682.10
52-Week Range	609.40 - 888.00
Beta	n/a
RSI	43.07
Earnings Date	Aug 7, 2025

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja...

• Industry: Pharmaceutical Preparations
• Founded: 1876
• Employees: 47,000
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1LLY

Financial Performance

In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Financial numbers in USD